Lakefront Biotherapeutics (GLPGF) Total Current Liabilities (2013 - 2026)

Lakefront Biotherapeutics (GLPGF) has reported Total Current Liabilities for 14 consecutive years, with $117.6 million the latest figure, recorded in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 74.43% year-over-year to $117.6 million in Q1 2026; TTM through Mar 2026 was $117.6 million, a 74.43% decrease from a year earlier, with the FY2025 full-year figure at $172.7 million, down 52.38% from the prior year.
• Total Current Liabilities was $117.6 million for Q1 2026 at Lakefront Biotherapeutics, down from $177.9 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $533.1 billion in Q4 2022 and troughed at $117.6 million in Q1 2026.
• A 5-year average of $41.4 billion and a median of $456.1 million in 2025 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities slumped 99.91% in 2023 and climbed 11.1% in 2025, its largest moves.
• Over 5 years, Total Current Liabilities stood at $533.1 billion in 2022, then tumbled by 99.91% to $460.7 million in 2023, then slipped by 22.28% to $358.1 million in 2024, then tumbled by 50.31% to $177.9 million in 2025, then plunged by 33.93% to $117.6 million in 2026.
• The last three Total Current Liabilities figures came in at $117.6 million (Q1 2026), $177.9 million (Q4 2025), and $428.5 million (Q3 2025), per Business Quant data.